← All trials
NCT01801904
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2012
- Primary completion
- Sep 1, 2017
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 52
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Fondazione Giovanni PascaleLead sponsor
- Azienda Sanitaria Rummo, Benevento, Division of Medical OncologyOverall official - principal investigator
- University of Campania Luigi VanvitelliOverall official - principal investigator
- Azienda Ospedaliera Antonio CardarelliOverall official - principal investigator
- Fondazione Giovanni PascaleOverall official - principal investigator
- Azienda Ospedaliera G. RummoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.